[go: up one dir, main page]

EA201270378A1 - Хиназолины в качестве ингибиторов калиевых каналов - Google Patents

Хиназолины в качестве ингибиторов калиевых каналов

Info

Publication number
EA201270378A1
EA201270378A1 EA201270378A EA201270378A EA201270378A1 EA 201270378 A1 EA201270378 A1 EA 201270378A1 EA 201270378 A EA201270378 A EA 201270378A EA 201270378 A EA201270378 A EA 201270378A EA 201270378 A1 EA201270378 A1 EA 201270378A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
quinazolins
potassium channels
potassium channel
function
Prior art date
Application number
EA201270378A
Other languages
English (en)
Other versions
EA021113B1 (ru
Inventor
Джеймс А. Джонсон
Джон Ллойд
Хезер Финлэй
Джи Джанг
Джеймс Нилс
Навин Кумар Донди
Прашанта Гунага
Абхисек Бэнерджи
Ашоккумар Адисечан
Original Assignee
Бристол-Майерс Сквибб Кампани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Кампани filed Critical Бристол-Майерс Сквибб Кампани
Publication of EA201270378A1 publication Critical patent/EA201270378A1/ru
Publication of EA021113B1 publication Critical patent/EA021113B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Catching Or Destruction (AREA)

Abstract

Соединение формулы Iгде значения А, X, Y, Z, Rи Rраскрыты в описании. Соединения применимы в качестве ингибиторов функции калиевого канала и для лечения и профилактики аритмии, I-ассоциированных заболеваний, и других заболеваний, опосредованных функцией калиевого канала.
EA201270378A 2009-09-03 2010-09-01 Хиназолины в качестве ингибиторов калиевых каналов EA021113B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23945209P 2009-09-03 2009-09-03
PCT/US2010/047430 WO2011028741A1 (en) 2009-09-03 2010-09-01 Quinazolines as potassium ion channel inhibitors

Publications (2)

Publication Number Publication Date
EA201270378A1 true EA201270378A1 (ru) 2012-07-30
EA021113B1 EA021113B1 (ru) 2015-04-30

Family

ID=42942118

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270378A EA021113B1 (ru) 2009-09-03 2010-09-01 Хиназолины в качестве ингибиторов калиевых каналов

Country Status (32)

Country Link
US (9) US8575184B2 (ru)
EP (3) EP2473487B1 (ru)
JP (2) JP5643312B2 (ru)
KR (1) KR101698631B1 (ru)
CN (1) CN102753535B (ru)
AR (1) AR078326A1 (ru)
AU (1) AU2010289641B2 (ru)
BR (1) BR112012008330B1 (ru)
CA (1) CA2772642C (ru)
CL (1) CL2012000583A1 (ru)
CO (1) CO6511220A2 (ru)
CY (2) CY1118488T1 (ru)
DK (2) DK3575288T3 (ru)
EA (1) EA021113B1 (ru)
ES (3) ES2609335T3 (ru)
HR (2) HRP20211973T1 (ru)
HU (2) HUE032983T2 (ru)
IL (1) IL218169A (ru)
LT (2) LT2473487T (ru)
MX (1) MX2012002099A (ru)
MY (1) MY160243A (ru)
NZ (1) NZ598516A (ru)
PE (1) PE20121153A1 (ru)
PL (2) PL2473487T3 (ru)
PT (2) PT3575288T (ru)
SG (1) SG178592A1 (ru)
SI (2) SI2473487T1 (ru)
SM (3) SMT202100717T1 (ru)
TN (1) TN2012000063A1 (ru)
TW (1) TWI488851B (ru)
WO (1) WO2011028741A1 (ru)
ZA (1) ZA201202383B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH068949B2 (ja) 1985-09-20 1994-02-02 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料
LT2473487T (lt) * 2009-09-03 2017-01-10 Bristol-Myers Squibb Company Chinazolinai kaip kalio jonų kanalų inhibitoriai
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
MX2013015204A (es) * 2011-06-29 2014-02-17 Otsuka Pharma Co Ltd Quinazolinas como compuestos terapeuticos, y metodos de uso relacionados.
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
CN103360382B (zh) * 2012-03-26 2016-04-27 中国科学院福建物质结构研究所 喹唑啉衍生物及其用途
PT2858987T (pt) * 2012-06-11 2018-07-04 Bristol Myers Squibb Co Profármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin -2-il]piridina-3-sulfonamida
EP2963019B1 (en) 2013-02-28 2020-08-12 Takeda Pharmaceutical Company Limited Method for producing pyridine-3-sulfonyl chloride
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
EP2970294B1 (en) 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
EP2970295B1 (en) * 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolopyridazines as potassium ion channel inhibitors
US9458133B2 (en) 2013-03-11 2016-10-04 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
EP3059233B1 (en) * 2013-10-17 2017-12-20 Sumitomo Chemical Company, Limited Tetrazolinone compound and application for same
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
JP6572891B2 (ja) 2014-06-10 2019-09-11 宇部興産株式会社 Ｎ−置換スルホンアミド化合物およびその製造方法
CA2951790C (en) 2014-06-10 2022-05-31 Ube Industries, Ltd. Method for producing heteroaromatic sulfonamide compound
AU2015357596A1 (en) * 2014-12-05 2017-06-29 Southern Research Institute Heterocyclic compounds as biogenic amine transport modulators
AU2015357505A1 (en) 2014-12-05 2017-06-29 Southern Research Institute Novel quinazolines as biogenic amine transport modulators
CA2988637A1 (en) * 2015-06-10 2016-12-15 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives
LT3458443T (lt) 2016-05-03 2020-11-10 Bayer Pharma Aktiengesellschaft Aromatiniai sulfonamido dariniai
CN106432067B (zh) * 2016-09-18 2019-04-19 北京天弘天达医药科技有限公司 一种3-吡啶磺酰氯的绿色化学合成方法
JP2021501178A (ja) * 2017-10-29 2021-01-14 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 虚血性脳卒中の治療のための芳香族スルホンアミド誘導体
SG11202009464PA (en) * 2018-04-20 2020-10-29 Bayer Ag Heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
US20220227729A1 (en) 2019-05-21 2022-07-21 Bayer Aktiengesellschaft Identification and use of kras inhibitors
EP4214204A1 (en) 2020-09-18 2023-07-26 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
WO2023212181A1 (en) * 2022-04-28 2023-11-02 University Of Miami Compounds for proliferative disorders
EP4587439A1 (en) 2022-09-16 2025-07-23 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
EP4602049A1 (en) 2022-10-13 2025-08-20 Bayer Aktiengesellschaft Sos1 inhibitors
WO2025202022A1 (en) 2024-03-27 2025-10-02 Bayer Aktiengesellschaft Anticancer macrocyclic quinazoline-based inhibitors of the ineraction between ras and sos1

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843791A (en) 1973-01-11 1974-10-22 Pfizer Method of killing insects with quinazolinones and quinazoline-thiones
DE69221175T2 (de) 1991-02-07 1998-01-15 Roussel Uclaf Bizyklische Stickstoffverbindungen, ihre Herstellung, erhaltene Zwischenprodukte, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
AU664337B2 (en) * 1993-06-17 1995-11-09 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
JPH083144A (ja) 1994-06-21 1996-01-09 Chugai Pharmaceut Co Ltd キナゾリン及びキノリン誘導体
TW414798B (en) 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1997020823A2 (en) * 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
ES2186908T3 (es) 1996-07-13 2003-05-16 Glaxo Group Ltd Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
AU7890598A (en) 1996-12-27 1998-07-31 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrimidine compounds and medicinal use thereof
WO1998038984A2 (en) 1997-03-05 1998-09-11 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
PL354323A1 (en) 1999-09-21 2004-01-12 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
NZ517575A (en) * 1999-09-30 2004-04-30 Neurogen Corp Certain alkylene diamine-substituted heterocycles
US6605615B2 (en) 2000-03-01 2003-08-12 Tularik Inc. Hydrazones and analogs as cholesterol lowering agents
JP3649395B2 (ja) 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
AU2001293817A1 (en) 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
EP1318985A2 (en) 2000-09-20 2003-06-18 MERCK PATENT GmbH 4-amino-quinazolines
WO2002062767A1 (fr) 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de quinazoline
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
WO2004030671A2 (en) 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
WO2004056801A1 (en) 2002-12-23 2004-07-08 Astrazeneca Ab Quinazoline derivatives
WO2004056812A1 (en) 2002-12-23 2004-07-08 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
WO2004069145A2 (en) 2003-02-07 2004-08-19 Dr. Reddy's Laboratories Ltd. Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
CL2004000409A1 (es) 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US7713983B2 (en) 2003-03-03 2010-05-11 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
CN1784391B (zh) * 2003-03-03 2010-06-09 沃泰克斯药物股份有限公司 可用作离子通道调控剂的喹唑啉
US20070010671A1 (en) 2003-03-31 2007-01-11 Yoshinori Sekiguchi Novel quinazoline derivatives and methods of treatment related to the use thereof
WO2004111057A1 (en) 2003-06-11 2004-12-23 Xention Discovery Limited Thienopyrimidine derivatives as potassium channel inhibitors
MXPA05013922A (es) 2003-06-20 2006-02-24 Coley Pharm Group Inc Antagonistas de receptor tipo toll de molecula pequena.
KR101218213B1 (ko) 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
JP4719681B2 (ja) * 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション キナゾリンカリウムチャネル阻害剤
EP1685115A1 (en) 2003-11-03 2006-08-02 Warner-Lambert Company LLC Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
EP1724268A4 (en) 2004-02-20 2010-04-21 Kirin Pharma Kk COMPOUNDS WITH TGF-BETA-HEMMENDER EFFECT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
EP1726584A4 (en) 2004-03-15 2009-05-13 Kyowa Hakko Kirin Co Ltd 2-AMINOCHINAZOLINDERIVAT
MXPA06014256A (es) 2004-06-10 2007-03-12 Xention Discovery Ltd Compuestos de furano-pirimidina efectivos como inhibidores del canal de potasio.
WO2006004722A2 (en) 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
EP1768964A1 (en) 2004-07-06 2007-04-04 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
ATE476434T1 (de) 2004-12-09 2010-08-15 Xention Ltd Thienopyridinderivate als kaliumkanalinhibitoren
JP2008526734A (ja) 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
AU2006214138A1 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Antiangiogenic agents with aldesleukin
JP4966958B2 (ja) 2005-03-14 2012-07-04 ノイロサーチ アクティーゼルスカブ カリウムチャネル調節剤及び医療における使用
MX2007011483A (es) 2005-03-23 2007-10-12 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de glutamato metabotropico 2.
BRPI0609650A2 (pt) 2005-03-25 2010-04-20 Tibotec Pharm Ltd inibidores heterobicìlicos de hvc
ES2369282T3 (es) 2005-03-25 2011-11-29 Tibotec Pharmaceuticals Inhibidores heterobicíclicos de vhc.
WO2006118256A1 (ja) 2005-04-28 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. 2-アミノキナゾリン誘導体
US20070049559A1 (en) 2005-06-28 2007-03-01 Bruce Pfeffer Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of Gelatinase A in ocular cells
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
WO2007071632A2 (en) 2005-12-20 2007-06-28 Neurosearch A/S 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
EP1968968A1 (en) 2005-12-21 2008-09-17 PainCeptor Pharma Corp. Compositions and methods for modulating gated ion channels
DE102006012251A1 (de) 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
WO2008003702A2 (en) 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Fused bicyclic compounds interacting with the histamine h4 receptor
WO2008023357A1 (en) 2006-08-22 2008-02-28 Technion Research And Development Foundation Ltd. Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr)
US20100173332A1 (en) 2006-09-07 2010-07-08 Auckland Uniservices Limited Method for the Fluorescent Detection of Nitroreductase Activity Using Nitro-Substituted Aromatic Compounds
WO2008045529A1 (en) 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
JP2010529031A (ja) 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
WO2009006141A2 (en) 2007-07-05 2009-01-08 Bausch & Lomb Incorporated Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CN101575333B (zh) 2008-05-09 2011-06-22 和记黄埔医药（上海）有限公司 一种喹唑啉衍生物及其医药用途
AU2009249106A1 (en) 2008-05-21 2009-11-26 Genentech, Inc. Arylsulfonamide compounds, compositions and methods of use
LT2473487T (lt) * 2009-09-03 2017-01-10 Bristol-Myers Squibb Company Chinazolinai kaip kalio jonų kanalų inhibitoriai
JP5792171B2 (ja) 2009-09-04 2015-10-07 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 白血病を治療するための組成物および方法
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos

Also Published As

Publication number Publication date
KR101698631B1 (ko) 2017-01-20
US10214511B2 (en) 2019-02-26
CA2772642C (en) 2017-08-29
PL3575288T3 (pl) 2022-01-24
US20230322726A1 (en) 2023-10-12
MX2012002099A (es) 2012-04-11
US20140031345A1 (en) 2014-01-30
US9458114B2 (en) 2016-10-04
PE20121153A1 (es) 2012-08-27
ZA201202383B (en) 2013-09-25
EP3575288A1 (en) 2019-12-04
SMT202100717T1 (it) 2022-01-10
CA2772642A1 (en) 2011-03-10
SMT201700026B (it) 2017-03-08
JP2013503875A (ja) 2013-02-04
US11008306B2 (en) 2021-05-18
SI2473487T1 (sl) 2017-02-28
BR112012008330B1 (pt) 2022-03-22
IL218169A (en) 2015-11-30
CY1118488T1 (el) 2017-07-12
PT2473487T (pt) 2017-01-04
CY1125021T1 (el) 2023-03-24
US20190144426A1 (en) 2019-05-16
CN102753535B (zh) 2015-03-25
DK2473487T3 (en) 2017-02-06
LT2473487T (lt) 2017-01-10
KR20120125978A (ko) 2012-11-19
HUE032983T2 (en) 2017-11-28
DK3575288T3 (da) 2021-12-20
AU2010289641A1 (en) 2012-03-22
ES2900504T3 (es) 2022-03-17
JP5643312B2 (ja) 2014-12-17
EP2473487A1 (en) 2012-07-11
ES2750598T3 (es) 2020-03-26
LT3575288T (lt) 2021-12-10
CN102753535A (zh) 2012-10-24
HRP20211973T1 (hr) 2022-03-18
SG178592A1 (en) 2012-04-27
MY160243A (en) 2017-02-28
PL2473487T3 (pl) 2017-07-31
CO6511220A2 (es) 2012-08-31
US20180030034A1 (en) 2018-02-01
US20120232068A1 (en) 2012-09-13
PT3575288T (pt) 2021-12-09
SMT201700026T1 (it) 2017-03-08
TW201113267A (en) 2011-04-16
AU2010289641B2 (en) 2015-05-07
HRP20161669T1 (hr) 2017-02-24
US20250230144A1 (en) 2025-07-17
NZ598516A (en) 2013-02-22
SI3575288T1 (sl) 2022-01-31
IL218169A0 (en) 2012-07-31
EP3124475A1 (en) 2017-02-01
HUE057433T2 (hu) 2022-05-28
EP3124475B1 (en) 2019-08-07
ES2609335T3 (es) 2017-04-19
US20220324836A1 (en) 2022-10-13
US10676460B2 (en) 2020-06-09
TN2012000063A1 (en) 2013-09-19
TWI488851B (zh) 2015-06-21
JP2015057410A (ja) 2015-03-26
CL2012000583A1 (es) 2012-08-31
EP3575288B1 (en) 2021-10-27
US20160362396A1 (en) 2016-12-15
EP2473487B1 (en) 2016-10-26
WO2011028741A1 (en) 2011-03-10
US9822096B2 (en) 2017-11-21
JP5950978B2 (ja) 2016-07-13
EA021113B1 (ru) 2015-04-30
US8575184B2 (en) 2013-11-05
US20200255407A1 (en) 2020-08-13
BR112012008330A2 (pt) 2021-02-17
AR078326A1 (es) 2011-11-02

Similar Documents

Publication Publication Date Title
EA201270378A1 (ru) Хиназолины в качестве ингибиторов калиевых каналов
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201290880A1 (ru) Новые соединения - ингибиторы фермента
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201290632A1 (ru) Производные бетулина
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
WO2007085895A3 (en) Fap inhibitors
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
EA201071100A1 (ru) Пиридилсодержащие ингибиторы передачи сигнала через белок hedgehog
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
UA104885C2 (ru) Изотиазолилоксифениламидины и их применение как фунгицидов
EP3715345A3 (en) Preparation of lfa-1 inhibitor and polymorph thereof
EA201290416A1 (ru) Новые спиропиперидиновые соединения
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
EA201200102A1 (ru) Соединения, применимые в качестве лекарственных средств
MX2012008141A (es) Compuestos y metodos.
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
ATE510822T1 (de) Kaliumkanalinhibitoren
ES2657549T3 (es) Piridopirazinas sustituidas como nuevos inhibidores de SYK
EA201490643A1 (ru) Новые производные бетулиновой кислоты с противовирусной активностью
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM